Mylan Inc. (MYL) Appoints Jacek Glinka as President of Mylan's European Business

PITTSBURGH, Oct. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Jacek Glinka as president of Mylan's European business, effective Dec. 2, 2013. Glinka will report to Hal Korman, Mylan's chief operating officer.

Prior to joining Mylan, Glinka served as chief executive officer for the Polpharma Group from 2003 to 2006 and from 2009 to 2013. During his tenure, Glinka led the transformation of Polpharma from a small local player into a leading pharmaceutical company in Central and Eastern Europe, the Caucasus and Central Asia. Under his leadership, Polpharma became the leader in the Polish market and one of the fastest growing pharmaceutical companies in the region. From 2011 to 2013, Polpharma doubled its revenue to more than $1 billion. Glinka also led Polpharma in the successful acquisition and integration of a number of businesses including Chimpharm in Kazakhstan; Polfa Warsaw inPoland; the antibiotics division of Bioton in Poland; and the nutraceuticals portfolio of Herbapol. Additionally, Glinka led the company's strategic expansion into new geographies, both organically and through acquisition, including Kazakhstan, Uzbekistan, Azerbaijan and Vietnam. He also enhanced the company's organizational structure and processes, and implemented several corporate-wide cost reduction programs resulting in substantial improvements in Polpharma's profitability.

Mylan CEO Heather Bresch commented, "We are thrilled to welcome Jacek to Mylan. His exceptional track record leading Polpharma speaks for itself and we believe his deep experience in the region will contribute to Mylan's continued success and growth in Europe. We believe Jacek's strong leadership, strategic thinking and operational discipline will build on the solid foundation and leadership team we already have in place, and maximize the many opportunities we see ahead for our European business."

Glinka said, "I have been following Mylan closely for some time and believe its massive global scale, vertical integration, broad product portfolio and unwavering commitment to quality are true differentiators in the highly competitive and diverse European market. I look forward to working with Mylan's global and regional leaders to continue to maximize the power of the Mylan platform across the region and further solidify Mylan's leadership positions in key markets. I also look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan's footprint."

Prior to leading Polpharma, Glinka was a managing director at Spectra Services, where he oversaw a number of acquisitions and restructurings, including the acquisition and integration of Akrihin into Polpharma Group. He began his professional career as a strategic management consultant with firms including Deloitte & Touche and A.T. Kearney.

Glinka has served as member of the supervisory boards of Medana Pharma, OAO Akrihin (president of the board), Chimpharm, Polfa Lublin (president of the board), Herbapol Lublin (vice president of the board), ZT Kruszwica and Spectra Investments. He received his degree from the Warsaw Business School.

This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; the ability to attract and retain key personnel; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

SOURCE Mylan Inc.